Introduction
The World Health Organization (WHO) envisions a world where every pregnant woman and newborn receives quality care throughout the pregnancy, childbirth and the postnatal period. Within the continuum of reproductive health care, antenatal care (ANC) provides a platform for important health-care functions, including health promotion, screening and diagnosis, and disease prevention. It has been established that by implementing timely and appropriate evidence-based practices, ANC can save lives. Crucially, ANC also provides the opportunity to communicate with and support women, families and communities at a critical time in the course of a woman's life. The process of developing these recommendations on ANC has highlighted the importance of providing effective communication about physiological, biomedical, behavioural and sociocultural issues, and effective support, including social, cultural, emotional and psychological support, to pregnant women in a respectful way. These communication and support functions of ANC are key, not only to saving lives, but to improving lives, healthcare utilization and quality of care. Women's positive experiences during ANC and childbirth can create the foundations for healthy motherhood. This is a comprehensive WHO guideline on routine ANC for pregnant women and adolescent girls. The aim is for these recommendations to complement existing WHO guidelines on the management of specific pregnancyrelated complications. The guidance is intended to reflect and respond to the complex nature of the issues surrounding the practice and delivery of ANC, and to prioritize person-centred health and well-beingnot only the prevention of death and morbidity -in accordance with a human rights-based approach.
The scope of this guideline was informed by a systematic review of women's views, which shows that women want a positive pregnancy experience from ANC. A positive pregnancy experience is defined as maintaining physical and sociocultural normality, maintaining a healthy pregnancy for mother and baby (including preventing or treating risks, illness and death), having an effective transition to positive labour and birth, and achieving positive motherhood (including maternal self-esteem, competence and autonomy).
Recognizing that a woman's experience of care is key to transforming ANC and creating thriving families and communities, this guideline addresses the following questions:
What are the evidence-based practices during ANC that improve outcomes and lead to a positive pregnancy experience?
How should these practices be delivered?
Guideline development methods
These ANC recommendations are intended to inform the development of relevant health-care policies and clinical protocols. The guideline was developed using standard operating procedures in accordance with the process described in the WHO handbook for guideline development. Briefly, these procedures include: (i) identification of priority questions and outcomes; (ii) evidence retrieval and synthesis; (iii) assessment of the evidence; (iv) formulation of the recommendations; and (v) planning for implementation, dissemination, impact evaluation and updating of the guideline. The quality of the scientific evidence underpinning the recommendations was graded using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) and Confidence in the Evidence from Reviews of Qualitative research (GRADE-CERQual) approaches, for quantitative and qualitative evidence, respectively. Up-to-date systematic reviews were used to prepare evidence profiles for priority questions. The DECIDE (Developing and Evaluating Communication Strategies to support Informed Decisions and Practice based on Evidence) framework, an evidence-to-decision tool that includes intervention effects, values, resources, equity, acceptability and feasibility criteria, was used to guide the formulation and approval of recommendations by the Guideline Development Group (GDG) -an international group of experts assembled for the purpose of developing this guideline -at three Technical Consultations between October 2015 and March 2016.
Recommendations
The WHO Technical Consultations led to the development of 39 recommendations related to five types of interventions: A. Nutritional interventions, B. Maternal and fetal assessment, C. Preventative measures, D. Interventions for common physiological symptoms, and E. Health systems interventions to improve utilization and quality of antenatal care. Interventions were either recommended, not recommended, or recommended under certain conditions based on the GDG's judgements according to the DECIDE criteria, which informed both the direction and context, if any, of the recommendation. To ensure that each recommendation is correctly understood and applied in practice, the context of all context-specific recommendations is clearly stated within each recommendation, and the contributing experts provided additional remarks where needed. Users of the guideline should refer to these remarks, which are presented along with the evidence summaries in the full version of the guideline. In addition, ANC-relevant recommendations from current guidance produced by other WHO departments were systematically identified and 10 such recommendations were consolidated into this guideline for the purpose of providing a comprehensive document for end-users. All 49 recommendations on ANC for a positive pregnancy experience are summarized in Table 1 .
In accordance with WHO guideline development standards, these recommendations will be reviewed and updated following the identification of new evidence, with major reviews and updates at least every five years. WHO welcomes suggestions regarding additional questions for inclusion in future updates of the guideline.
At the Technical Consultations, the implementation considerations of individual recommendations and of the guideline as a whole were discussed. The GDG, emphasizing the evidence indicating increased fetal deaths and lesser satisfaction of women with the four-visit model (also known as focused or basic ANC), decided to increase the recommended number of contacts between the mother and the health-care providers at time points that may facilitate assessment of well-being and provision of interventions to improve outcomes if problems are identified (see Recommendation E.7 in Table 1 ). The recommendations in this guideline should be implemented alongside other quality-improvement activities. Derivative products of this guideline will include a practical implementation manual for health-care practitioners, which will incorporate ANC recommendations and established good clinical practices. Table 1 summarizes the list of all interventions evaluated by the guideline panels and therefore includes interventions that are recommended, only recommended under certain conditions (including research), and interventions that are not recommended. These recommendations apply to pregnant women and adolescent girls within the context of routine ANC
A. Nutritional interventions

Recommendation
Type of recommendation
Dietary interventions
A.1.1: Counselling about healthy eating and keeping physically active during pregnancy is recommended for pregnant women to stay healthy and to prevent excessive weight gain during pregnancy.
Recommended
A.1.2:
In undernourished populations, nutrition education on increasing daily energy and protein intake is recommended for pregnant women to reduce the risk of low-birth-weight neonates.
Context-specific recommendation
A.1.3:
In undernourished populations, balanced energy and protein dietary supplementation is recommended for pregnant women to reduce the risk of stillbirths and small-for-gestational-age neonates.
Context-specific recommendation
A.1.4:
In undernourished populations, high-protein supplementation is not recommended for pregnant women to improve maternal and perinatal outcomes.
Not recommended
Iron and folic acid supplements
A.2.1:
Daily oral iron and folic acid supplementation with 30 mg to 60 mg of elemental iron 2 and 400 µg (0.4 mg) of folic acid 3 is recommended for pregnant women to prevent maternal anaemia, puerperal sepsis, low birth weight, and preterm birth. 4 
Recommended
A.2.2:
Intermittent oral iron and folic acid supplementation with 120 mg of elemental iron 5 and 2800 µg (2.8 mg) of folic acid once weekly is recommended for pregnant women to improve maternal and neonatal outcomes if daily iron is not acceptable due to side-effects, and in populations with an anaemia prevalence among pregnant women of less than 20%. 6 Context-specific recommendation Calcium supplements
A.3:
In populations with low dietary calcium intake, daily calcium supplementation (1.5-2.0 g oral elemental calcium) is recommended for pregnant women to reduce the risk of pre-eclampsia. 7 
Context-specific recommendation
Vitamin A supplements A.4: Vitamin A supplementation is only recommended for pregnant women in areas where vitamin A deficiency is a severe public health problem, 8 to prevent night blindness. Context-specific recommendation 1 A healthy diet during pregnancy contains adequate energy, protein, vitamins and minerals, obtained through the consumption of a variety of foods, including green and orange vegetables, meat, fish, beans, nuts, whole grains and fruit. 2 The equivalent of 60 mg of elemental iron is 300 mg of ferrous sulfate hepahydrate, 180 mg of ferrous fumarate or 500 mg of ferrous gluconate. 3 Folic acid should be commenced as early as possible (ideally before conception) to prevent neural tube defects. 4 This recommendation supersedes the previous WHO recommendation (1). 5 The equivalent of 120 mg of elemental iron equals 600 mg of ferrous sulfate heptahydrate, 360 mg of ferrous fumarate or 1000 mg of ferrous gluconate. 6 This recommendation supersedes the previous WHO recommendation (2) . 15 This is not a recommendation on routine screening for hyperglycaemia in pregnancy. This recommendation has been adapted and integrated from the 2013 WHO publication (8) , which states that GDM should be diagnosed at any time in pregnancy if one or more of the following criteria are met:
• fasting plasma glucose 5.1-6.9 mmol/L (92-125 mg/dL)
• 1-hour plasma glucose ≥ 10.0 mmol/L (180 mg/dL) following a 75 g oral glucose load
• 2-hour plasma glucose 8.5-11.0 mmol/L (153-199 mg/dL) following a 75 g oral glucose load.
Diabetes mellitus in pregnancy should be diagnosed if one or more of the following criteria are met:
• fasting plasma glucose ≥ 7.0 mmol/L (126 mg/dL)
• 2-hour plasma glucose ≥ 11.1 mmol/L (200 mg/dL) following a 75 g oral glucose load
• random plasma glucose ≥ 11.1 mmol/L (200 mg/dL) in the presence of diabetes symptoms. 16 Integrated from the 2013 WHO recommendations (9). 17 Integrated from the 2014 WHO guidelines (10).
18 High-prevalence settings are defined as settings with greater than 5% HIV prevalence in the population being tested. Lowprevalence settings are those with less than 5% HIV prevalence in the population being tested (11) . In settings with a generalized or concentrated HIV epidemic, retesting of HIV-negative women should be performed in the third trimester because of the high risk of acquiring HIV infection during pregnancy. 19 Adapted and integrated from WHO's Consolidated guidelines on HIV testing services (11) . 
Tetanus toxoid vaccination C.5: Tetanus toxoid vaccination is recommended for all pregnant women, depending on previous tetanus vaccination exposure, to prevent neonatal mortality from tetanus. 25 Recommended 21 Cardiotocography is a continuous recording of the fetal heart rate and uterine contractions obtained via an ultrasound transducer placed on the mother's abdomen. 22 Doppler ultrasound technology evaluates umbilical artery (and other fetal arteries) waveforms to assess fetal well-being in the third trimester of pregnancy. 23 Areas with greater than 20% prevalence of infection with any soil-transmitted helminths.
24 Consistent with the 2016 WHO guideline (13) . 25 This recommendation is consistent with the 2006 WHO guidelines (14) . The dosing schedule depends on the previous tetanus vaccination exposure.
Recommendations integrated from other WHO guidelines that are relevant to ANC
Malaria prevention: intermittent preventive treatment in pregnancy (IPTp) C.6: In malaria-endemic areas in Africa, intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP) is recommended for all pregnant women. Dosing should start in the second trimester, and doses should be given at least one month apart, with the objective of ensuring that at least three doses are received.
26
Context-specific recommendation Pre-exposure prophylaxis (PrEP) for HIV prevention C.7: Oral pre-exposure prophylaxis (PrEP) containing tenofovir disoproxil fumarate (TDF) should be offered as an additional prevention choice for pregnant women at substantial risk of HIV infection as part of combination prevention approaches. Recommended 26 Integrated from the 2015 WHO guidelines, which also state: "WHO recommends that, in areas of moderate-to-high malaria transmission of Africa, IPTp-SP be given to all pregnant women at each scheduled ANC visit, starting as early as possible in the second trimester, provided that the doses of SP are given at least 1 month apart. WHO recommends a package of interventions for preventing malaria during pregnancy, which includes promotion and use of insecticide-treated nets, as well as IPTp-SP" (15) . To ensure that pregnant women in endemic areas start IPTp-SP as early as possible in the second trimester, policy-makers should ensure health system contact with women at 13 weeks of gestation. 27 Integrated from the 2015 WHO guidelines (16) . Substantial risk of HIV infection is defined by an incidence of HIV infection in the absence of PrEP that is sufficiently high (> 3% incidence) to make offering PrEP potentially cost-saving (or cost-effective). Offering PrEP to people at substantial risk of HIV infection maximizes the benefits relative to the risks and costs. 
E.4.1:
The implementation of community mobilization through facilitated participatory learning and action (PLA) cycles with women's groups is recommended to improve maternal and newborn health, particularly in rural settings with low access to health services.
28
Participatory women's groups represent an opportunity for women to discuss their needs during pregnancy, including barriers to reaching care, and to increase support to pregnant women.
Context-specific recommendation
E.4.2:
Packages of interventions that include household and community mobilization and antenatal home visits are recommended to improve antenatal care utilization and perinatal health outcomes, particularly in rural settings with low access to health services.
Context-specific recommendation
Task shifting components of antenatal care delivery 29 E.5.1: Task shifting the promotion of health-related behaviours for maternal and newborn health 30 to a broad range of cadres, including lay health workers, auxiliary nurses, nurses, midwives and doctors is recommended. Recommended E.5.2: Task shifting the distribution of recommended nutritional supplements and intermittent preventive treatment in pregnancy (IPTp) for malaria prevention to a broad range of cadres, including auxiliary nurses, nurses, midwives and doctors is recommended.
Recommended
Recruitment and retention of staff in rural and remote areas 31 E.6: Policy-makers should consider educational, regulatory, financial, and personal and professional support interventions to recruit and retain qualified health workers in rural and remote areas.
Context-specific recommendation
Antenatal care contact schedules E.7: Antenatal care models with a minimum of eight contacts are recommended to reduce perinatal mortality and improve women's experience of care.
Recommended 28 Integrated from the 2014 WHO recommendations (17) . 29 Recommendations adapted and integrated from the 2012 WHO OptimizeMNH guideline (18). 30 Including promotion of the following: care-seeking behaviour and ANC utilization; birth preparedness and complication readiness; sleeping under insecticide-treated bednets; skilled care for childbirth; companionship in labour and childbirth; nutritional advice; nutritional supplements; other context-specific supplements and interventions; HIV testing during pregnancy; exclusive breastfeeding; postnatal care and family planning; immunization according to national guidelines. 31 Recommendation adapted and integrated from the 2010 WHO global policy recommendations (19) . 
